The prognosis for GIST patients depends on various factors, including tumor size, location, mitotic rate, and the presence of mutations. Generally, smaller tumors with low mitotic rates have a better prognosis. The advent of TKIs has significantly improved survival rates for patients with advanced or metastatic GISTs.
